Please login to the form below

Not currently logged in
Email:
Password:

darapladib

This page shows the latest darapladib news and features for those working in and with pharma, biotech and healthcare.

GSK takes anti-inflammatory drug into phase III as heart therapy

GSK takes anti-inflammatory drug into phase III as heart therapy

GSK's cardiovascular pipeline suffered a setback last month when coronary artery disease therapy darapladib failed a second phase III trial.

Latest news

  • Second darapladib failure disappoints GSK Second darapladib failure disappoints GSK

    Second darapladib failure disappoints GSK. Drug unable to demonstrate effectiveness in acute coronary syndrome. ... Prospects for GlaxoSmithKline's coronary artery disease therapy darapladib have all but disappeared after it failed to show efficacy in a

  • Moving parts Moving parts

    Meanwhile, costly phase III failures arrived in the shape of Lilly's depression drug edivoxetine and GlaxoSmithKline's highly anticipated new coronary heart disease drug candidate darapladib, which both flunked

  • GSK hit as darapladib flunks phase III test GSK hit as darapladib flunks phase III test

    GSK hit as darapladib flunks phase III test. Heart disease drug disappoints in late-stage trial. ... GlaxoSmithKline's highly anticipated new coronary heart disease (CHD) drug candidate darapladib has disappointed in a phase III trial.

  • GSK's Chinese sales hit by scandal, say analysts GSK's Chinese sales hit by scandal, say analysts

    darapladib for atherosclerosis which could have "vast potential" if it reaches the market.

  • GSK submits albiglutide for European approval GSK submits albiglutide for European approval

    Albiglutide is, along with lupus treatment Benlysta and heart disease drug darapladib, one of a trio of drugs GSK has developed with Human Genome Sciences.

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... There is $150m in potential licence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics